Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Salivary Gland Neoplasms 1Prostatic Neoplasms 1

Interventions

pembrolizumab 602Cyclophosphamide 545Magnetic Resonance Spectroscopy 524Radiotherapy 513Specimen Handling 506Nivolumab 412Cisplatin 380Carboplatin 368Biopsy 306Blood Specimen Collection 302Radiosurgery 290Paclitaxel 280Surveys and Questionnaires 270Gemcitabine 270Standard of Care 267Drug Therapy 263Dexamethasone 263fludarabine 262Bevacizumab 253venetoclax 251Oxaliplatin 209Capecitabine 201Rituximab 198Radiation 192Fluorouracil 189Ipilimumab 188durvalumab 184Doxorubicin 179Etoposide 176atezolizumab 175

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Androgen Receptor Antagonists × 1 year × Clear all
NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1/2 Recruiting
52 enrolled
Genitourinary

Prostatic Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡